Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Singapore's wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutical company, Grifols said on Wednesday.

Singapore's sovereign fund invests $1 billion in Grifols's U.S. unit

BARCELONA, Spain, June 1, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and IgG products for patients, today began commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin [human] for hepatitis B postexposure prophylaxis. The new formulation, which was approved by the U.S. Food and Drug Administration (FDA) in December 2020, uses a unique caprylate chromatography process, which significantly reduces procoagulant activity and IgG aggregates.

Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B

The center will collect real-world data on AMBAR® clinical program - AMBAR® Center combines Grifols' more than 15 years of knowledge researching this devastating disease with the experience of the non-profit medical foundation Ace Alzheimer Center Barcelona in diagnosing and treating Alzheimer's patients, including application of AMBAR® (Alzheimer Management by Albumin Replacement) - The AMBAR® clinical program, based on periodic plasma exchange with albumin, has shown a delay in the cognitive and functional progression of Alzheimer's disease in mild-to-moderate patients - Ace Alzheimer Center will manage the center, to be located on its premises in Barcelona. Grifols will partner with other leading medical institutions to open expected future centers in the EU, U.S. and China, obtaining AMBAR® data from clinical practice and advancing further in the therapeutic management of the disease BARCELONA, Spain, May 19, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, today announced it's collaborating with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR ® Center, where AMBAR ® procedure for Alzheimer's disease will be applied to obtain data from clinical practice.

Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona

BARCELONA, Spain, April 28, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, today announced it has signed an agreement with the government of Andorra through Andorra Development and Investment (ADI) to establish a global R+D+i hub to advance knowledge of the human immune system and investigate and develop new immune therapies. The planned facility, the Pyrenees Immunology Research Center (PYIRC), will focus on developing treatments for immune system disorders that can result in diseases including autoimmunity disorders, cancer and emerging infectious diseases.

Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics

A. O. Smith

Cboe Global Markets

ICON

Medical Properties Trust

According to the GuruFocus discounted cash flow calculator as of April 21, the following companies have a high margin of safety and have grown their margins over a 10-year period.

5 Profitable Stocks With a Margin of Safety

Grifols operates in the very attractive and lucrative plasma business.

Grifols: The Plasma-Supply Disruption Provides An Attractive Entry Point

BARCELONA, Spain, April 15, 2021   /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that it will donate a minimum of 240 million international units (IU) of blood clotting factor medicines (Factor VIII and Factor IX) to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over the next eight years, from 2022 to 2030. This contribution extends the company's commitment that began in 2014 and will bring its total humanitarian aid commitment to more than 440M IU of Factor VIII and Factor IX over 16 years.

Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030

BARCELONA, Spain, April 9, 2021 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 9, 2021.

Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021

BARCELONA, Spain, April 2, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial, also known as INSIGHT-013, sponsored and supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its primary endpoints with statistically significant results. The company will continue to move forward with its work on more than 20 research initiatives to find potential treatment options for different stages of COVID-19.

Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

BARCELONA, Spain, March 22, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of innovative diagnostic solutions, today announced its first-ever installation in North America of the DG Reader Net semi-automated analyzer, used to facilitate pre-transfusion blood type compatibility testing. This platform, the newest addition to the company's scalable solutions for blood banks, is now running at ThedaCare Medical Center-Wild Rose in Wisconsin.

Grifols installs first-ever DG Reader Net analyzer in North America

BARCELONA, Spain, March 9, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people worldwide, today announced the closing of its agreement...

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Grifols

Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.

Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug

BARCELONA, Spain, Jan. 18, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced it...

Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19

Good prospects for the global immunoglobulin business. Koru Medical's strategic plan is to reach $ 50M in sales by 2022, a gross margin of 70%, and organic and annual sales growth of + 20%.

Portfolio Manager Diary: Contrast The Information Obtained By The Company Management Before Investing

Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider Grifols (GRFS) Stock Now?

BARCELONA, Spain, Nov. 16, 2020 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more than 100 years of history contributing to improve people's health and well-being, has...

The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies

BARCELONA, Spain, Nov. 12, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and provider of technologies and services for hospitals, clinics and compounding centers, today announced a partnership with TRC...

Grifols partners with TRC Healthcare to streamline intravenous compounding education

Oligopoly of four companies that control more than 80% of the plasma business. Secular growth trend for population aging.

Grifols Class B: Buy The Recovery In The U.S. Plasma Business

Ross Stores

HelloFresh SE

Industria de Diseno Textil SA

Fund boosts holding in Buffett's conglomerate, announces management changes

Bestinfond's Top 5 Buys of the 3rd Quarter

The Spanish market has gotten crushed with an uptick in COVID-19 deaths. Grifols stock is about where it was when I visited headquarters three years ago.

Grifols Looks Enticing After Big Sell-Off In Spain

BARCELONA, Spain, Oct. 9, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that...

Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19

- The investment includes a fractionation plant with a 1.5 million-liter annual capacity and two purification plants, making Grifols the only large-scale commercial manufacturer of plasma products in Canada - This transaction highlights Grifols' commitment to supporting countries such as...

Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

Arch Capital

Ameriprise Financial

Boston Properties

Martin Marietta Materials

According to the GuruFocus All-in-One Screener, a Premium feature, the following companies have high business predictability ratings and wide margins of safety as of Sept. 28.

5 Guru Stocks With Predictable Businesses

Blood plasma and diagnostics company Grifols SA (NASDAQ: GRFS) is set to completely acquire Alkahest Inc, a biopharmaceutical startup focussed on neurodegenerative and age-related diseases, for $146 million on a debt-free basis.

News for Grifols, S.A. Stock (GRFS)